The predictive value of PROMIS self-efficacy on HRQoL in patients from the Almenara Lupus Cohort
| Vitality | Social functioning | Role emotional | Mental health | |||||
| B (SE) | p value | B (SE) | p value | B (SE) | p value | B (SE) | p value | |
| Self-efficacy for managing daily activities | 0.14 (0.11) | 0.204 | 0.71 (0.15) | <0.001 | 1.26 (0.32) | <0.001 | 0.35 (0.10) | <0.001 |
| Self-efficacy for managing symptoms | 0.12 (0.11) | 0.286 | 0.55 (0.14) | <0.001 | 0.91 (0.27) | <0.001 | 0.40 (0.09) | <0.001 |
| Self-efficacy for managing medications and treatment* | 0.04 (0.10) | 0.684 | 0.19 (0.14) | 0.162 | 0.82 (0.30) | 0.006 | 0.27 (0.10) | 0.004 |
| Self-efficacy for managing emotions | 0.13 (0.10) | 0.199 | 0.55 (0.16) | <0.001 | 0.60 (0.28) | 0.032 | 0.25 (0.10) | 0.015 |
| Self-efficacy for managing social interactions | 0.20 (0.12) | 0.086 | 0.53 (0.14) | <0.001 | 0.88 (0.27) | 0.001 | 0.40 (0.11) | <0.001 |
| General self-efficacy | 0.08 (0.08) | 0.371 | 0.39 (0.12) | 0.001 | 0.68 (0.23) | 0.003 | 0.24 (0.09) | 0.006 |
Adjusted for age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SLICC/American College of Rheumatology Damage Index, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and the same domain in the previous visit.
Values in bold are those that are statistically significant.
*Only patients taking at least one medication were included in these analyses.
HRQoL, health-related quality of life; PROMIS, Patient-Reported Outcomes Measurement Information System; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2K; SLICC, Systemic Lupus International Collaborating Clinics.